- Country: South Korea
- Summary: 2022 Intractable Lung Cancer Treatment for Overcoming Exosite Bio New Drug Analysis Platform Planning Report
- KRT Ref No: 64203369
- Deadline: 18 Mar 2022
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: KRW 222472732224727
- Notice Type: Tender
- Document Ref. No.: 20220312380-00
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- 2022 intractable lung cancer therapy for overcoming exosite bio new drug analysis platform planning report
Reference Number: My KBSI22-Service-04
Assignment Budget: 24,472,000 won
Estimated price: 22,247,273 won (VAT: 2,224,727)
Bid start date: 2022/03/16 09:00:00:00
Bidding Finish: 2022/03/18 10:00:00:00 - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGIN2022 Intractable Lung Cancer Treatment for Overcoming Exosite Bio New Drug Analysis Platform Planning Report - Korea Tender
The KOREA BASIC SCIENCE SUPPORT RESEARCH INSTITUTE, a Government sector organization in South Korea, has announced a new tender for 2022 Intractable Lung Cancer Treatment for Overcoming Exosite Bio New Drug Analysis Platform Planning Report. This tender is published on KoreaTenders under KRT Ref No: 64203369 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2022-03-18.
The estimated tender value is KRW 222472732224727, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
